Dean Capital Investments Management LLC Has $836,000 Stock Holdings in Sanofi SA (NYSE:SNY)

Share on StockTwits

Dean Capital Investments Management LLC lessened its holdings in Sanofi SA (NYSE:SNY) by 21.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,048 shares of the company’s stock after selling 5,064 shares during the period. Sanofi makes up 0.5% of Dean Capital Investments Management LLC’s portfolio, making the stock its 20th biggest position. Dean Capital Investments Management LLC’s holdings in Sanofi were worth $836,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. Fisher Asset Management LLC raised its position in Sanofi by 3.0% in the third quarter. Fisher Asset Management LLC now owns 17,377,003 shares of the company’s stock worth $805,077,000 after purchasing an additional 508,580 shares in the last quarter. Morgan Stanley grew its stake in Sanofi by 34.1% during the second quarter. Morgan Stanley now owns 3,145,435 shares of the company’s stock worth $136,104,000 after buying an additional 800,612 shares during the last quarter. Northern Trust Corp grew its stake in Sanofi by 2.5% during the second quarter. Northern Trust Corp now owns 2,275,495 shares of the company’s stock worth $98,461,000 after buying an additional 56,394 shares during the last quarter. Wells Fargo & Company MN grew its stake in Sanofi by 3.0% during the second quarter. Wells Fargo & Company MN now owns 1,561,586 shares of the company’s stock worth $67,570,000 after buying an additional 45,335 shares during the last quarter. Finally, Royal Bank of Canada grew its stake in Sanofi by 12.4% during the second quarter. Royal Bank of Canada now owns 1,425,413 shares of the company’s stock worth $61,677,000 after buying an additional 157,222 shares during the last quarter. 7.04% of the stock is owned by hedge funds and other institutional investors.

In other news, major shareholder Sanofi sold 172,904 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $281.15, for a total transaction of $48,611,959.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.00% of the stock is owned by corporate insiders.

Shares of SNY traded up $0.09 during mid-day trading on Tuesday, hitting $45.95. 52,702 shares of the company traded hands, compared to its average volume of 1,307,250. Sanofi SA has a one year low of $40.00 and a one year high of $47.47. The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40. The business has a 50-day moving average of $45.83 and a 200 day moving average of $43.41. The stock has a market capitalization of $114.86 billion, a price-to-earnings ratio of 14.68, a PEG ratio of 2.41 and a beta of 0.67.

Several analysts have weighed in on the stock. Sanford C. Bernstein assumed coverage on shares of Sanofi in a research note on Tuesday, September 3rd. They set an “outperform” rating and a $52.00 price objective on the stock. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Monday, October 14th. UBS Group raised shares of Sanofi from a “neutral” rating to a “buy” rating in a research note on Wednesday, August 14th. Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $47.00 price objective on the stock in a research note on Thursday, August 29th. Finally, Morgan Stanley raised shares of Sanofi from an “equal” rating to a “weight” rating in a research note on Friday, September 20th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $49.50.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Article: What is the Beige Book?

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.